venBio Partners LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001776382 · Show all filings

Period: Q3 2019 (← Previous) (Next →)

Filing Date: May 20, 2020

Total Value: $211M (100.0% shares, 0.0% debt)

Holdings (6)

— AKERO THERAPEUTICS INC 42.7%

Value $89.97M Shares 3,954,858 Est. Cost $19.15 Unrealized —

— TURNING POINT THERAPEUTICS I 23.9%

Value $50.39M Shares 1,340,265 Est. Cost $40.70 Unrealized —

— PRECISION BIOSCIENCES INC 17.0%

Value $35.78M Shares 4,265,141 Est. Cost $17.95 Unrealized —

APLS APELLIS PHARMACEUTICALS INC 11.4%

Value $24.09M Shares 1,000,000 Est. Cost $15.34 Unrealized +79.4%

— MENLO THERAPEUTICS INC 3.1%

Value $6.548M Shares 1,461,552 Est. Cost $4.12 Unrealized —

— VERONA PHARMA PLC 1.9%

Value $3.999M Shares 875,000 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	AKERO THERAPEUTICS INC	3,954,858	$89.97M	42.7%	$19.15	—	COM	00973Y108
—	TURNING POINT THERAPEUTICS I	1,340,265	$50.39M	23.9%	$40.70	—	COM	90041T108
—	PRECISION BIOSCIENCES INC	4,265,141	$35.78M	17.0%	$17.95	—	COM	74019P108
APLS	APELLIS PHARMACEUTICALS INC	1,000,000	$24.09M	11.4%	$15.34	+79.4%	COM	03753U106
—	MENLO THERAPEUTICS INC	1,461,552	$6.548M	3.1%	$4.12	—	COM	586858102
—	VERONA PHARMA PLC	875,000	$3.999M	1.9%	$9.65	—	SPONSORED ADS	925050106